Literature DB >> 16407390

Secondary amyloidosis in Crohn's disease: treatment with tumour necrosis factor inhibitor.

M M Boscá, C M Pérez-Baylach, M A Solis, R Antón, E Mayordomo, S Pons, M Mínguez, A Benages.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16407390      PMCID： PMC1856509          DOI： 10.1136/gut.2005.082057

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  10 in total

1.  Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab.

Authors:  Ori Elkayam; Philip N Hawkins; Helen Lachmann; Michael Yaron; Dan Caspi
Journal:  Arthritis Rheum       Date:  2002-10

2.  Current therapeutic possibilities in primary and secondary amyloidosis and our experience with 31 patients.

Authors:  R Rysavá; M Merta; I Spicka; V Tesar
Journal:  Nephrol Dial Transplant       Date:  2003-07       Impact factor: 5.992

Review 3.  Molecular mechanisms of amyloidosis.

Authors:  Giampaolo Merlini; Vittorio Bellotti
Journal:  N Engl J Med       Date:  2003-08-07       Impact factor: 91.245

4.  [Brown bowel syndrome: diagnostic and therapeutic problems].

Authors:  J Bort Marti; A Redondo Camp; F Miró Silvestre; L Aparisi Quereda; M T Chiquillo Barber; F Vera Sempere; A Benages Martínez
Journal:  Rev Esp Enferm Dig       Date:  1992-04       Impact factor: 2.086

Review 5.  Acute-phase proteins and other systemic responses to inflammation.

Authors:  C Gabay; I Kushner
Journal:  N Engl J Med       Date:  1999-02-11       Impact factor: 91.245

Review 6.  The systemic amyloidoses.

Authors:  R H Falk; R L Comenzo; M Skinner
Journal:  N Engl J Med       Date:  1997-09-25       Impact factor: 91.245

7.  Resolution of primary amyloidosis by melphalan and prednisolone: a case report.

Authors:  M Nakayama; M Kashiwagi; R Katafuchi; K Hori; S Hayashi; S Fujimi
Journal:  Clin Nephrol       Date:  2005-03       Impact factor: 0.975

8.  Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy.

Authors:  Jacques-Eric Gottenberg; Florence Merle-Vincent; Fabrice Bentaberry; Yannick Allanore; Francis Berenbaum; Bruno Fautrel; Bernard Combe; Antoine Durbach; Jean Sibilia; Maxime Dougados; Xavier Mariette
Journal:  Arthritis Rheum       Date:  2003-07

9.  [Secondary amyloidosis (AA) and renal disease].

Authors:  E Torregrosa; J Hernández-Jaras; C Calvo; A Ríus; H García-Pérez; F Maduell; J M Vera
Journal:  Nefrologia       Date:  2003 Jul-Aug       Impact factor: 2.033

10.  [Inflammatory bowel disease and amyloidosis].

Authors:  M Iñarrairaegui Bastarrica; A Arín Letamendia; J M Zozaya Urmeneta; C Rodríguez Gutiérrez; B Castán Martínez; I Amat Villegas; R Beloqui Pérez
Journal:  Gastroenterol Hepatol       Date:  2004-04       Impact factor: 2.102
  10 in total
  1 in total

Review 1.  Management of cutaneous disorders related to inflammatory bowel disease.

Authors:  Zaira Pellicer; Jesus Manuel Santiago; Alejandro Rodriguez; Vicent Alonso; Rosario Antón; Marta Maia Bosca
Journal:  Ann Gastroenterol       Date:  2012
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.